The company plans to launch 14 products in Brazil, targeting a potential market of USD 2 billion, expanding access to high-complexity treatments in key therapeutic areas, expecting to generate over USD 130 million in sales within the next 4 years. Through strategic...
CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. This marks CStone’s third major global commercialization partnership for...
